In the management of a patient with a deep venous thrombosis (DVT), which direct oral anticoagulant (DOAC) can be used without injectable therapy?

Study for the Board Certified Cardiology Pharmacist Exam. Utilize flashcards and answer multiple-choice questions with detailed explanations. Prepare efficiently for your certification!

Multiple Choice

In the management of a patient with a deep venous thrombosis (DVT), which direct oral anticoagulant (DOAC) can be used without injectable therapy?

Rivaroxaban is the only direct oral anticoagulant (DOAC) among the choices listed that can be used for the initial treatment of a patient with deep venous thrombosis (DVT) without the need for prior injectable anticoagulation therapy. Typically, the management of DVT often starts with parenteral anticoagulants, such as heparin or low molecular weight heparin, followed by the initiation of a vitamin K antagonist or a DOAC. However, rivaroxaban has clinical data supporting its use as a monotherapy for DVT treatment from the onset. The recommended dosing allows patients to start rivaroxaban directly, without the overlap required by some other medications, making it more convenient and facilitating earlier anticoagulation control. In contrast, the other anticoagulants listed require a period of injectable therapy before transitioning to oral administration: - Edoxaban requires a parenteral anticoagulant for at least 5 days before initiating the oral form, as it is important to establish therapeutic levels of anticoagulation initially. - Dabigatran is also initiated after a minimum of 5 days of parenteral anticoagulation for similar reasons. - Apixaban falls into the category where it

Rivaroxaban is the only direct oral anticoagulant (DOAC) among the choices listed that can be used for the initial treatment of a patient with deep venous thrombosis (DVT) without the need for prior injectable anticoagulation therapy.

Typically, the management of DVT often starts with parenteral anticoagulants, such as heparin or low molecular weight heparin, followed by the initiation of a vitamin K antagonist or a DOAC. However, rivaroxaban has clinical data supporting its use as a monotherapy for DVT treatment from the onset. The recommended dosing allows patients to start rivaroxaban directly, without the overlap required by some other medications, making it more convenient and facilitating earlier anticoagulation control.

In contrast, the other anticoagulants listed require a period of injectable therapy before transitioning to oral administration:

  • Edoxaban requires a parenteral anticoagulant for at least 5 days before initiating the oral form, as it is important to establish therapeutic levels of anticoagulation initially.

  • Dabigatran is also initiated after a minimum of 5 days of parenteral anticoagulation for similar reasons.

  • Apixaban falls into the category where it

More practice questions